Chronic Pruritus | VPD-737 for Treatment of Chronic Pruritus
Chronic Pruritus research study
What is the primary objective of this study?
A study of a several doses of a novel treatment for chronic itch compared to placebo for
patients whose condition has not responded to other treatments
Who is eligible to participate?
- Clinical diagnosis of chronic pruritus and unresponsive to current therapies
- Have chronic liver or renal disease
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:VPD-737NK1 Receptor Antagonist
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
0.25 mg VPD-7370.25 mg of VPD-737 daily by mouth for 42 days
1 mg VPD-7371 mg VPD-737 taken daily by mouth for 42 days
5 mg VPD-7375 mg tablets of VPD-737 to be taken daily by mouth for 42 days
Placeboplacebo tablets to be taken daily by mouth for 42 days
Start Date: October 2013
Completed Date: April 2015
Phase: Phase 2
Primary Outcome: Visual Analog Scale
Secondary Outcome: Verbal Response Scale
Study sponsors, principal investigator, and references
Principal Investigator: Edward F Schnipper, MD
Lead Sponsor: Menlo Therapeutics Inc.